Bayer Builds Cardiovascular Franchise With Possis Purchase
This article was originally published in The Gray Sheet
Executive Summary
Bayer HealthCare will expand its cardiovascular device offerings by acquiring AngioJet thrombectomy system maker Possis Medical for $361 million under a deal announced Feb. 11
You may also be interested in...
Research In Brief
G.I. Liner: GI Dynamics' EndoBarrier gastrointestinal liner significantly reduces average blood glucose levels in patients with type 2 diabetes, according to results of a three-month, 18-patient, sham-controlled pilot study presented at the First World Congress on Interventional Therapies for Type 2 Diabetes in New York Sept. 16. The data, presented by Lee Kaplan, M.D./Ph.D, Harvard Medical School, show that the 12 patients treated with EndoBarrier in the trial experienced a mean reduction in average blood glucose of 2.9% from a baseline of 8.9%, compared to a reduction of 0.76% from a baseline of 9% in the six patients in the sham control group. EndoBarrier is an endoscopically implantable barrier that creates a duodenal-jejunal bypass to prevent food from contacting the intestinal wall. Investigators believe the bypass reduces a patient's uptake of both nutrients and calories and creates a similar metabolic effect as Roux-en-Y gastric bypass surgery, which has been shown to promote weight loss and resolution of type 2 diabetes. The firm plans to launch a major trial of an enhanced version of EndoBarrier in 2009
Research In Brief
G.I. Liner: GI Dynamics' EndoBarrier gastrointestinal liner significantly reduces average blood glucose levels in patients with type 2 diabetes, according to results of a three-month, 18-patient, sham-controlled pilot study presented at the First World Congress on Interventional Therapies for Type 2 Diabetes in New York Sept. 16. The data, presented by Lee Kaplan, M.D./Ph.D, Harvard Medical School, show that the 12 patients treated with EndoBarrier in the trial experienced a mean reduction in average blood glucose of 2.9% from a baseline of 8.9%, compared to a reduction of 0.76% from a baseline of 9% in the six patients in the sham control group. EndoBarrier is an endoscopically implantable barrier that creates a duodenal-jejunal bypass to prevent food from contacting the intestinal wall. Investigators believe the bypass reduces a patient's uptake of both nutrients and calories and creates a similar metabolic effect as Roux-en-Y gastric bypass surgery, which has been shown to promote weight loss and resolution of type 2 diabetes. The firm plans to launch a major trial of an enhanced version of EndoBarrier in 2009
Possis shareholder lawsuit dismissed
U.S. Court of Appeals for the Eighth Circuit on March 24 affirms a previous decision by the U.S. District Court for the District of Minnesota to dismiss with prejudice a shareholder lawsuit filed June 5, 2005 against Minneapolis endovascular device firm Possis Medical and two of its executive officers. The suit had alleged the firm misrepresented material information about the company's AngioJet Rheolytic thrombectomy system prior to its August 2004 disclosure of results from its AiMI clinical trial, Possis said. Bayer HealthCare acquired Possis for $361 million in February (1"The Gray Sheet" Feb. 18, 2008, p. 10)